DIABETES: Metformin — a cardiovascular moderator of DPP4 inhibitors?

    loading  Checking for direct PDF access through Ovid

Abstract

Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.

Refers to Crowley, M. J. et al. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Carehttp://dx.doi.org/10.2337/dc17-1528 (2017)

Related Topics

    loading  Loading Related Articles